| MDA-MB-231 |
Human breast cancer |
APCP |
Xenograft of MDA-MB-231 cells in nude mice with APCP treatment have a lower volume and weight than those of the control group [50] |
| |
|
Anti-CD73 (AD2) |
Anti-CD73 monoclonal antibody inhibits metastasis formation by a mechanism independent of CD73 catalytic activity but fails to inhibit primary tumor growth [110] |
| |
|
SiRNA-CD73 |
CD73 siRNA effectively causes MB-MDA-231 tumor growth suppression in vitro and in vitro, prevention of adhesion to extracellular matrix and inhibition of invasion and migration [28,31] |
| U138MG |
Human brain glioblastoma |
APCP |
In vitro APCP treatment of glioma cells results in a significant reduction of glioma cell proliferation [111] |
| T24 |
Human bladder carcinoma |
APCP |
In vitro APCP treatment results in a significant decrease of T24 cell number as compared with control cells [51] |
| GBC-SD |
Human gallbladder carcinoma |
SiRNA-CD73 |
CD73 knockdown inhibits tumor cell proliferation, migration and motility [112] |
| Glioblastoma Multiforme |
Human brain cancer |
SiRNA-CD73 |
CD73 knockdown reverses multiple-drug resistance of GBM cells [33] |
| E0771 |
Murine breast cancer |
Anti-CD73 (TY/23) |
Anti-CD73 monoclonal antibody treatment significantly delays primary E0771 tumor growth in immune-competent mice [24] |
| ID8 |
Murine ovarian cancer |
APCP |
A survival advantage is observed in ID8-bearing mice with APCP treatment in vivo [25] |
| |
|
Anti-CD73 (TY/23) |
Peritoneal ID8 tumor model showed a median 146-day survival of mice treated with TY/23 as superior to that of mice without treatment [18] |
| ID8-OVA |
Murine ovarian cancer |
SiRNA-CD73 |
CD73 knockdown renders tumor cells more susceptible to T-cell killing [25] |
| B16-SIY |
Murine melanoma |
APCP |
In vivo APCP treatment effectively suppresses B16-SIY tumor growth [18] |
| |
|
Anti-CD73 (TY/23) |
Delayed tumor growth was observed in B16-SIY bearing mice treated with the anti-CD73 mAb TY/23 as compared with a control group [18] |
| B16F10 |
Murine melanoma |
APCP |
In vivo APCP treatment induces significant tumor regression by promoting the release of Th1- and Th17-associated cytokines in the tumor microenvironment [104] |
| |
|
CD73 ablation |
CD73 ablation significantly suppresses the growth and metastasis of B16F10 [18] |
| 4T1.2 |
Murine breast cancer |
Anti-CD73 (TY/23) |
Anti-CD73 monoclonal antibody treatment significantly delays primary 4T1.2 and E0771 tumor growth in immune-competent mice and significantly inhibits the development of spontaneous 4T1.2 lung metastases [24] |
| 4T1 |
Murine breast cancer |
siRNA-CD73 loaded nanoparticle |
Decreased expression of tumor cell CD73 contributes to decreased tumor growth and metastasis and improves animal subject survival [113,114] |
| MCA-induced fibrosarcoma |
Murine |
Anti-CD73 (TY/23) |
Anti-CD73 monoclonal antibody treatment effectively suppresses growth of established 3-methylcholanthrene (MCA)-induced tumors [19] |
| |
|
CD73 ablation |
CD73 deficiency suppresses the development of MCA-induced fibrosarcomas [19] |
| TRAMP-C1 |
Murine prostate cancer |
Anti-CD73 (TY/23) |
Anti-CD73 monoclonal antibody treatment suppresses the growth of TRAMP-C1 prostate tumors and inhibits the development of TRAMP-C1 lung metastases [19] |
| Prostate cancer |
Murine |
CD73 ablation |
CD73 deficiency also suppresses prostate tumorigenesis in TRAMP transgenic mice [19] |
| LWT1 |
Murine melanoma |
Anti-CD73 (TY/23) |
Anti-CD73 monoclonal antibody treatment significantly decreases metastatic burden as compared with control treatment [115] |
| |
|
CD73 ablation |
CD73 ablation improves metastatic control as compared with wild-type mice [115] |
| MC38-OVA |
Murine colon cancer |
CD73 ablation |
CD73 ablation significantly suppresses the growth of MC38-OVA [26] |
| EL4/EG7 |
Murine lymphoma |
CD73 ablation |
CD73 ablation significantly suppresses the growth of EL4/EG7 [18,26] |
| AT-3 |
Murine mammary tumor |
CD73 ablation |
CD73 ablation significantly suppresses the growth of AT-3 [26] |
